PR5-LL-CM01|cas:1005307-86-7|西域试剂

PR5-LL-CM01,98.45%

产品编号：Bellancom-109963| CAS NO：1005307-86-7| 分子式：C₂₃H₂₇N₇| 分子量：401.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109963	￥1200.00	杭州北京（现货）
Bellancom-109963	￥2000.00	杭州北京（现货）
Bellancom-109963	￥3900.00	杭州北京（现货）
Bellancom-109963	￥6000.00	杭州北京（现货）
Bellancom-109963	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PR5-LL-CM01

产品介绍

PR5-LL-CM01 是一种有效的 (PRMT5) 抑制剂 (IC₅₀= 7.5 μM)。PR5-LL-CM01 具有抗肿瘤活性。

生物活性

PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC₅₀= 7.5 μM). Anti-tumor activies.

体外研究

PR5-LL-CM01 has a range of IC₅₀ at 2-4 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1, and a range of IC₅₀ at 10-11 μM in CRC cells (HT29, HCT116 and DLD1). PR5-LL-CM01 has higher efficacy to specifically inhibit cancer cells and demonstrated low toxicity in normal cells. PR5-LL-CM01 strongly inhibited colony forming ability in both PANC1 and HT29 cells.
PR5-LL-CM01 inhibits NF-κB activation and its target gene expression in PDAC and CRC cells.
PR5-LL-CM01 (0-15 μM) dramatically decreases TNFα and IL8 expression in both PANC1 and HT29 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PR5-LL-CM01 (20mg/kg; i.p.; 3 times per week) displays significant anti-tumor effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 weeks old Male NSG mice (bearing PANC1 or HT29 cells)
Dosage:	20 mg/kg (drug stock dissolved in 1:1 Cremophor:ethanol solution)
Administration:	Intraperitoneally 3 times per week; 32 days (PANC1 model); 10 days (HT29 model)
Result:	Led to significant tumor inhibition in both PANC1 and HT29 xenografted mice. Did not visibly affect the mice body weight.

体内研究

PR5-LL-CM01 (20mg/kg; i.p.; 3 times per week) displays significant anti-tumor effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 weeks old Male NSG mice (bearing PANC1 or HT29 cells)
Dosage:	20 mg/kg (drug stock dissolved in 1:1 Cremophor:ethanol solution)
Administration:	Intraperitoneally 3 times per week; 32 days (PANC1 model); 10 days (HT29 model)
Result:	Led to significant tumor inhibition in both PANC1 and HT29 xenografted mice. Did not visibly affect the mice body weight.

性状

Solid

溶解性数据

In Vitro:

DMSO : 11.11 mg/mL (27.67 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4906 mL	12.4530 mL	24.9060 mL
5 mM	0.4981 mL	2.4906 mL	4.9812 mL
10 mM	0.2491 mL	1.2453 mL	2.4906 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献